EXHIBIT 10.74







Execution Copy




 



CONSENT, TRANSFER, ASSUMPTION AND AMENDMENT AGREEMENT







This Consent, Transfer, Assumption and Amendment Agreement (the “Loan Transfer Consent” or this “Agreement”), is made and entered into as of August 12, 2013, by and among (i) XOMA Ireland Limited, a company with limited liability incorporated organized and existing under the laws of Ireland (registered number 307875), having its registered head office at 26 Upper Pembroke Street, Dublin 2, Ireland (“XOMA Ireland”), (ii) XOMA (US) LLC, a limited liability company organized and existing under the laws of Delaware, having its registered office at 2910 Seventh Street, Berkeley, California 94710, USA (“XOMA US”), and (iii) Les Laboratoires Servier, a corporation organized and existing under the laws of France, 50 rue Carnot, 92284 Suresnes, France (“SERVIER”).







WITNESSETH:







WHEREAS, XOMA Ireland and SERVIER entered into a Loan Agreement dated December 30, 2010 (the “Loan Agreement”), pursuant to which SERVIER made the Advance to XOMA Ireland;







WHEREAS, in connection with and pursuant to the Loan Agreement, the following documents were delivered and filed:








		Ø	XOMA Ireland issued a Promissory Note to SERVIER on January 13, 2011 with a principal amount equal to the Advance (the “Original Note”);











		Ø	XOMA Ireland and SERVIER entered into a Fixed Charge (the “Fixed Equitable Charge”) dated January 13, 2011 pursuant to which XOMA Ireland charged certain contractual and intellectual property rights (the “Collateral”) related to its proprietary IL-1β antibody designated gevokizumab (formerly known as XOMA 052 and/or S-78989, “GEVO”) as a security for the benefit of SERVIER to guarantee the repayment of the amounts due to SERVIER pursuant to the Loan Agreement;











		Ø	the Fixed Equitable Charge was registered with the Irish Companies Registry on January 25, 2011;











		Ø	XOMA Ltd., XOMA Ireland’s parent company organized under the laws of Bermuda, issued a Guarantee to SERVIER on December 30, 2010, to guarantee the payment by XOMA Ireland to SERVIER of all amounts due under the Loan Agreement (the “XOMA Ltd. Guarantee”); and











		Ø	XOMA US issued a Guarantee to SERVIER on December 30, 2010, to guarantee the payment by XOMA Ireland to SERVIER of all amounts due under the Loan Agreement (the “XOMA US Guarantee”).










WHEREAS, XOMA Ireland has entered into an Asset Transfer Agreement (the “Asset Transfer Agreement”) with its Affiliate, XOMA US, pursuant to which they have, subject to the satisfaction of certain conditions, agreed to (i) the transfer by XOMA Ireland to XOMA US of various assets relating to GEVO, including the Collateral and (ii) the assumption by XOMA US of certain liabilities of XOMA Ireland, including under the Loan Agreement and the Loan Documents (collectively, the “GEVO Asset Transfer”), the completion of which in accordance with the terms of the Asset Transfer Agreement is expected to occur on or about August 12, 2013 or at such other date as may be notified in writing at least 5 days prior to the occurrence thereof, by XOMA US to SERVIER (the “Transfer Completion Date”);














Execution Copy


 




WHEREAS, XOMA Ireland wishes to obtain SERVIER’s consent to the transfer of the Loan Agreement to XOMA US in accordance with Section 9.2 thereof, to the termination and release of the Fixed Equitable Charge and corresponding registration with the Irish Companies Registry and to various other matters relating to the Loan Agreement that are necessary or useful to enable XOMA Ireland to complete the GEVO Asset Transfer;







WHEREAS, SERVIER is willing to provide such consents subject to (a) XOMA US undertaking to assume and perform all of XOMA Ireland’s obligations under the Loan Agreement in accordance with and as modified by the terms hereof, and (b) the satisfaction of the Conditions (as defined in Section 3.1.1 below); and







WHEREAS, XOMA US is willing to assume XOMA Ireland’s obligations under the Loan Agreement and to deliver to SERVIER and file such documents.







NOW, THEREFORE, in consideration of the covenants and conditions set forth below, the Parties hereto, intending to be legally bound, hereby agree to the following:







ARTICLE 1 – TRANSFER OF LOAN AGREEMENT








	1.1	Subject to Section 3.1, SERVIER hereby irrevocably consents to the transfer of all of XOMA Ireland’s rights and obligations under the Loan Agreement to XOMA US.











	1.2	Effective as of the Transfer Completion Date, all references to XOMA Ireland in the Loan Agreement shall be deemed to refer to XOMA US and XOMA Ireland shall have no further obligations under the Loan Agreement.











	1.3	XOMA US hereby irrevocably agrees effective as of the Transfer Completion Date to assume all of XOMA Ireland’s obligations under the Loan Agreement and shall perform and discharge all such obligations in accordance with the terms thereof.











	1.4	The representations and warranties contained in Article 5 of the Loan Agreement, shall be true and correct as of the Transfer Completion Date, provided that: (a) each reference in such provisions to XOMA Ireland shall be deemed to refer to XOMA US, and (b) for purposes of Sections 5.1 and 5.4 of the Loan Agreement, each representation and warranty by XOMA Ireland as an Irish limited company shall mean and refer to XOMA US, a Delaware limited liability company, with all such representations and warranties meaning and referring to XOMA US as such.










ARTICLE 2 – AMENDMENT








	2.1	Termination and Replacement of the Fixed Equitable Charge.











	2.1.1	Subject to Section 3.1, XOMA Ireland, SERVIER and XOMA US agree that the Fixed Equitable Charge shall be cancelled and released effective as of the Transfer Completion Date.











2







Execution Copy


 



	2.1.2	Subject to Section 3.1, SERVIER shall at the latest on the Transfer Completion Date deliver to XOMA US a Deed of Release in substantially the form attached as Exhibit 3 hereto dated as of the date hereof giving effect to SERVIER’s cancellation and release of the Fixed Equitable Charge.











	2.1.3	The definition “Fixed Equitable Charge” in Section 1.2 of the Loan Agreement shall be deleted in its entirety and replaced by the definition of “Security Agreement” set out in Section 3.1 hereof.  All references to the term “Fixed Equitable Charge” in the Loan Agreement shall thereinafter be understood as referring to the Security Agreement.











	2.2	Cancellation and Replacement of the Note.











	2.2.1	Subject to Section 3.1, the Original Note shall be cancelled and of no further effect and validity effective as of the Transfer Completion Date, and replaced by the XOMA US Note (as defined in Section 3.1 hereof) in accordance with terms hereof.  Upon receipt of the XOMA US Note, SERVIER shall deliver to XOMA Ireland the cancelled Original Note.











	2.2.2	All references to the term “Note” in the Loan Agreement shall thereinafter refer to the XOMA US Note.











	2.3	Cancellation of the XOMA US Guarantee to SERVIER.











	2.3.1	Subject to Section 3.1, the XOMA US Guarantee shall be terminated and of no further effect effective as of the Transfer Completion Date.











	2.4	Tax Cooperation.











	2.4.1	Effective as of the Transfer Completion Date, the first three sentences of Section 3.10(a) of the Loan Agreement shall be deleted in their entirety and replaced by the following text:










“(a)            The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding or similar obligations in respect of payments of interest and other Indebtedness made by XOMA US to Servier under this Loan Agreement. XOMA US agrees that under the current French/United States Tax Treaty, payments made by XOMA US to Servier under this Loan Agreement are not subject to withholding tax in the United States so long as Servier provides XOMA US a valid Certificate of Foreign Status of Beneficial Owner for United States Tax Withholding (“Form W-8BEN”) evidencing its eligibility for a reduced withholding tax rate of 0% under the current French/United States Tax Treaty. Servier shall provide to XOMA US, who shall complete any required portions of, any tax forms that may be reasonably necessary in order for XOMA US not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, including a valid Form W-8BEN (“Tax Forms”).”







The remainder of Section 3.10(a) shall remain unchanged, other than the replacement of XOMA Ireland by XOMA US.


 




	2.4.2	Effective as of the Transfer Completion Date, Section 3.10(b) of the Loan Agreement shall be deleted in its entirety and replaced by the following text:





 





3







Execution Copy


 


“(b)            If despite Servier’s submission of the Tax Forms, XOMA US is required by US tax laws to deduct any taxes from any amount payable under this Loan Agreement or any Note, (i) the sum payable shall be increased as necessary so that after making all required deductions (including deductions applicable to additional sums payable under this Section 3.10(b)), Servier receives an amount equal to the sum it would have received had no such deductions been made, (ii) XOMA US shall make such deductions, (iii) XOMA US shall pay the full amount deducted to the relevant governmental authority in accordance with applicable law and (iv) XOMA US shall furnish to Servier evidence of such payment as may be reasonably acceptable to Servier; provided, however, that XOMA US’ obligations under this Section 3.10(b) shall not be applicable to the extent that (x) the withholding results from any modification in Servier’s tax status or (y) Servier is able to obtain a reimbursement of or credit for the withheld amount.”








	2.5	Effective as of the Transfer Completion Date, Section 9.4 (Notices) of the Loan Agreement shall be amended by including the following as XOMA US’ address and designated contact person for notices:










XOMA (US) LLC


2910 Seventh Street


Berkeley, CA 94710


United States


Attention: Chief Financial Officer


FAX: 510-649-0315








	2.6	Effective as of the Transfer Completion Date, all references to the Republic of Ireland in the Loan Agreement shall be amended to refer to the State of Delaware.











	2.7	Effective as of the Transfer Completion Date, all references in the Loan Agreement toBelgium law and Belgium choice of law shall be changed to New York law and NewYork choice of law; and Sections 9.6 (Governing Law) and 9.7 (Binding Arbitration) of the Loan Agreement shall be deleted and replaced by Section 9 of the Security Agreement, which shall be incorporated by reference to the Loan Agreement and apply thereto mutatis mutandis.











	2.8	Effective as of the Transfer Completion Date, the definition of “Collateral” set forth in Section 1.1 of the Loan Agreement shall be deleted in its entirety and replaced by the following text:










““Collateral” shall have the meaning ascribed thereto in the Security Agreement.”


 


ARTICLE 3 – CONDITIONS TO EFFECTIVENESS – RELEASE








	3.1	Conditions to Effectiveness.











	3.1.1	XOMA Ireland and XOMA US acknowledge and agree that, pursuant to the terms of the Loan Agreement, SERVIER’s consent is required prior to any transfer of the Loan Agreement, and that SERVIER’s consent given in this Loan Transfer Consent and the amendments in Article 2 hereof are subject to the prior satisfaction of the Conditions. Upon the satisfaction of the Conditions, SERVIER undertakes to deliver to XOMA Ireland and XOMA US a written confirmation of the Conditions having been satisfied, in substantially the form set out in Exhibit 4 hereto.











4








Execution Copy


 




For the purposes hereof “Conditions” shall mean (a) the completion of the GEVO Asset Transfer as evidenced by the delivery by XOMA US to SERVIER of a written confirmation thereof, and (b) the delivery, at the latest on the Transfer Completion Date, to SERVIER of (i) a replacement promissory note by XOMA US in favor of SERVIER in substantially the form set out in Exhibit 2 hereto (the “XOMA US Note”), and (ii) a security agreement in substantially the form set out in Exhibit 1 hereto pursuant to which XOMA US will grant a security interest in the Collateral to SERVIER to secure all of the obligations of XOMA US under the Loan Agreement, the Loan Documents and the XOMA US Note (the “Security Agreement”).








	3.1.2	Subject to the satisfaction of the Conditions, SERVIER acknowledges and agrees that neither the consummation of the Asset Transfer Agreement and the GEVO Asset Transfer nor the transfer of the Collateral to XOMA US in accordance with the terms and conditions of the Asset Transfer Agreement and this Loan Transfer Consent shall constitute a breach or default under the Loan Agreement.











	3.2	Release. Subject to the satisfaction of the Conditions, SERVIER consequently releases XOMA Ireland from any and all obligations towards SERVIER under the Loan Agreement as of the Transfer Completion Date. Similarly, subject to the satisfaction of the Conditions, XOMA Ireland consequently releases SERVIER from any and all obligations towards XOMA Ireland under the Loan Agreement as of the Transfer Completion Date.





 


ARTICLE 4 – POST-COMPLETION COVENANTS








	4.1	Reimbursement of Costs. XOMA US covenants to pay or reimburse the reasonable fees and out-of-pocket expenses of outside counsel incurred by SERVIER in connection with the preparation, execution and delivery of this Loan Transfer Consent and the related agreements.











	4.2	Patent Transfer Registration. Following the Transfer Completion Date (within three (3) months for European Union countries and within six (6) months for all other countries listed below), XOMA US (or an appropriate affiliate) and XOMA Ireland shall carry out all formalities that are necessary or helpful to register with the relevant regional or national patent offices in the countries / regions listed below the transfer to XOMA US of the rights in the patent applications or patents, as applicable, that are transferred to XOMA US in connection with the transactions contemplated by the Asset Transfer Agreement. XOMA US and XOMA Ireland shall thereafter use their respective best efforts to have this transfer registered promptly after the filing of such transfer request.










The list of countries / regions is: European Union, China, Russia, Indonesia, Turkey, South Korea, South Africa, Australia and Canada. There are, among the patent applications and patents relating to GEVO to be transferred to XOMA US in connection with the GEVO Asset Transfer, no patent applications or patents in Egypt.







XOMA US and XOMA Ireland’s obligation under this Section 4.2 shall include registering any previous transfer of the rights in the patent applications or patents, as applicable, that are transferred to XOMA US in connection with the transactions contemplated by the Asset Transfer Agreement if and where such supplementary registration is required for the purpose of registering the transfer to XOMA US of such rights.








5








Execution Copy


 




Servier shall reimburse all reasonable out-of-pocket expenses, including registration fees, translation fees and outside patent and legal counsel fees, incurred by XOMA US (or an appropriate affiliate) and/or XOMA Ireland in connection with these patent right transfer registrations.







ARTICLE 5 – MISCELLANEOUS








	5.1	Further Assurances. XOMA Ireland, XOMA US and SERVIER hereby covenant that each will, at any time and from time to time upon request by any other, and without the assumption of any additional liability thereby, execute and deliver such further documents and do such further acts as such party may reasonably request in order to fully effect the purpose of this Loan Transfer Consent











	5.2	Counterparts. This Loan Transfer Consent may be executed in any number of counterparts, each of which shall be deemed an original, but all of which when taken together shall constitute but one and the same agreement.











	5.3	Governing Law - Arbitration. This Loan Transfer Consent shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.  The provisions of Section 9 of the Security Agreement are hereby incorporated by reference and this Agreement and the parties hereto shall otherwise be subject to all of the terms and conditions of Section 9 of the Security Agreement, mutatis mutandis.











	5.4	All capitalized terms used but not defined in this Loan Transfer Consent shall have the meanings ascribed thereto in the Loan Agreement.











	5.5	Except as explicitly amended hereby, the Loan Agreement remains in full force and effect.










IN WITNESS WHEREOF, the parties hereto have executed or caused this Loan Transfer Consent to be executed as of the date first above written.







[Remainder of page intentionally left blank; signature page follows.]








6








Execution Copy







	
XOMA Ireland Limited

		
XOMA (US) LLC


	 		 
	
By: /s/ Alan Kane

		
By: /s/ James R. Neal


	
Name: Alan Kane

		
Name: James R. Neal


	
Title: Director

		
Title: VP, Business Development


	 		 
	
LES LABORATOIRES SERVIER

		 
	
By: /s/ Marie Christine Larcher

		 
	
Name: Marie Christine Larcher

		 
	
Title: Legal Affairs Director

		 















Execution Copy


 




EXHIBIT 1







SECURITY AGREEMENT







This Security Agreement (this “Agreement”) is made and entered into as of _____, 2013 by and between XOMA (US) LLC, a Delaware limited liability company (“Debtor”), and LES LABORATOIRES SERVIER, a corporation organized and existing under the laws of France (the “Secured Party”).







Recitals







Whereas, XOMA Ireland Limited (“XOMA Ireland”) and Secured Party are parties to that certain Amended and Restated Collaboration and License Agreement, dated February 14, 2012 (the “Collaboration and License Agreement”), a Loan Agreement, dated December 30, 2010 (as amended from time to time, the “Loan Agreement”), a Promissory Note, dated January 13, 2011, issued by XOMA Ireland to Secured Party (the “Original Note”), and a Fixed Charge, dated January 13, 2011, granted by XOMA Ireland in favor of Secured Party (the “Ireland Fixed Charge”).







Whereas, pursuant to that certain Asset Transfer Agreement, dated of even date herewith, by and between XOMA Ireland and Debtor and that certain Consent, Transfer, Assumption and Amendment Agreement, dated of even date herewith, by and among XOMA Ireland, the Secured Party and Debtor (the “Assumption Agreement”) (collectively, the “Asset Transfer Documents”), XOMA Ireland intends to transfer certain assets, including, without limitation, certain assets relating to the Collaboration and License Agreement, and certain rights and obligations under the Loan Agreement to Debtor, as further set forth in the Asset Transfer Documents.







Whereas, pursuant to the Assumption Agreement, Debtor will assume all of the obligations and rights of XOMA Ireland under the Loan Agreement, which the Secured Party has consented to, and the Original Note and Ireland Fixed Charge will be cancelled and released by the Secured Party upon the satisfaction of the conditions contained in the Assumption Agreement.


 


Whereas, the parties intend that a new Promissory Note, dated of even date herewith, will be issued by Debtor to Secured Party (as amended from time to time, the “XOMA US Promissory Note” and, collectively with the Loan Agreement, following the execution of the Assumption Agreement, the “Secured Agreements”), and Debtor and Secured Party wish to secure performance and payment of all obligations of Debtor to Secured Party under the Loan Agreement and the XOMA US Promissory Note (the “Obligations”) with liens on certain assets as described herein, in favor of Secured Party.  All terms used without definition in this Agreement shall have the meaning assigned to them in the Asset Transfer Documents and the Secured Agreements.  All terms used without definition in this Agreement, the Asset Transfer Documents, or the Secured Agreements shall have the meaning assigned to them in the UCC.








1








Execution Copy


 




Now, Therefore, Debtor and the Secured Party agree as follows:







1.            Grant of Security Interest.  To secure all of the Obligations and the performance by Debtor of its obligations under the Secured Agreements, Debtor grants to the Secured Party a security interest in the property described in Exhibit A (the “Collateral”).


 


2.            Debtor’s Representations and Warranties.  Debtor represents and warrants as follows:


 


(a)            Authorization.  Debtor has authority and has obtained all approvals and consents necessary to enter into this Agreement, and Debtor’s execution, delivery and performance of this Agreement will not violate or conflict with the terms of Debtor’s Limited Liability Company Agreement or other charter document, or any law, agreement, or other instrument or writing to which Debtor is party or by which is it bound.


 


(b)            Title.  The Collateral is owned by Debtor and is free and clear of all liens, encumbrances and other security interests.


 


(c)            Solvency, Payment of Debts.  (a) Debtor is able to pay its debts and other liabilities, contingent obligations and other commitments as they mature in the ordinary course of business, (b) Debtor does not intend to, and does not believe that it will, incur debts or liabilities beyond its ability to pay such debts and liabilities as they mature in the ordinary course of business, (c) Debtor is not engaged in a business or a transaction, and is not about to engage in a business or a transaction, for which its property would constitute unreasonably small capital under applicable laws and after giving due consideration to the prevailing practice in the industry in which it is engaged or is to engage, (d) the fair value of the property of Debtor is greater than the total amount of liabilities, including contingent liabilities, of Debtor and (e) the present fair salable value of the property of Debtor is not less than the amount that will be required to pay the probable liability of Debtor on its debts as they become absolute and matured.  In computing the amount of contingent liabilities at any time, it is intended that such liabilities will be computed at the amount which, in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.


 


(d)            Further Representations.  Debtor further represents, warrants, and covenants that (i) Debtor is not in default under any agreement under which Debtor owes any money, or any agreement, the violation or termination of which could have a material adverse effect on Debtor; (ii) the information provided to Secured Party on or prior to the date of this Agreement is true and correct in all material respects; (iii) Debtor is in compliance with all laws and orders applicable to it; (iv) Debtor is not a party to any litigation or is the subject of any government investigation, and Debtor has no knowledge of any pending litigation or investigation or the existence of circumstances that reasonably could be expected to give rise to such litigation or investigation; (v) Debtor’s principal place of business is located at the address specified in this Agreement; (vi) Debtor is a limited liability company organized under the laws of the State of Delaware; (vii) Debtor has not granted any security interest in the Collateral; (vii) each of the representations and warranties contained in the Loan Agreement and the other Loan Documents shall be true and correct as of the date hereof, provided that each reference in such provisions to XOMA Ireland shall be deemed to refer to the Debtor, and as otherwise modified in the Assumption Agreement; and (ix) no representation or other statement made by Debtor to Secured Party contains any untrue statement of a material fact or omits to state a material fact necessary to make any statements made to Secured Party not misleading.








2








Execution Copy


 




3.            Covenants.


 


(a)            Encumbrances.  Debtor shall (i) not grant a security interest in any of the Collateral other than to Secured Party or (ii) execute, or consent to the filing of, any financing statements covering any of the Collateral in favor of any person other than Secured Party.


 


(b)            Perfection of Security Interest.  Debtor shall execute and deliver such documents as Secured Party reasonably deems necessary to create, perfect and continue the security interest in the Collateral contemplated hereby.


 


(c)            Records.  Debtor shall prepare and keep, in accordance with generally accepted accounting principles consistently applied, complete and accurate records regarding the Collateral and, if and when requested by Secured Party, shall prepare and deliver a complete and accurate schedule of all the Collateral in such detail as Secured Party may reasonably require.


 


(d)            Fees and Costs.  Debtor shall pay all expenses, including reasonable attorneys’ fees, incurred by Secured Party in the preservation, realization, enforcement or exercise of any Secured Party’s rights under this Agreement.


 


(e)            Company Existence.  Debtor will maintain its company existence and good standing and will maintain in force all licenses and agreements, the loss of which could have a material adverse effect on Debtor's business.  Debtor will pay all taxes on or before the date such taxes are due, and will comply with all laws and orders applicable to it.


 


(f)            Negative Covenant.  Debtor will not (i) relocate its chief executive office, or change its name or state of organization, without at least 30 days prior written notice to Secured Party, or (ii) sell, lease, transfer or otherwise dispose of any of the Collateral without Secured Party’s prior written consent.


 


(g)            Further Assurances.  At any time and from time to time, upon the written request of Secured Party, and at the sole expense of Debtor, Debtor shall promptly and duly execute and deliver any and all such further instruments and documents and take such further action as Secured Party may reasonably deem desirable to obtain the full benefits of this Agreement and of the rights and powers herein granted, including, without limitation, (a) to secure all consents and approvals necessary or appropriate for the grant of a security interest to Secured Party in any Collateral held by Debtor or in which Debtor has any rights not heretofore assigned, (b)  execute, acknowledge and deliver all deeds, conveyances, assignments, demises, mortgages, charges, documents and assurances at law as are necessary or advisable or as the Secured Party may reasonably require for the better granting, conveying, assigning, transfer, demising or charging the same, and every such further to the Secured Party for the purpose referred to in this Section 3.1(h) and for conferring upon the Secured Party such power of sale and other powers over the said property as are expressed to be conferred by this Agreement, and (b) filing any financing or continuation statements under the UCC with respect to the security interests granted hereby.  Debtor also hereby authorizes Secured Party to file any such financing or continuation statement without the signature of Debtor.








3







Execution Copy


 


(h)            This Agreement will be a continuing security notwithstanding any settlement of account or other matter or thing whatsoever and in particular will not be considered satisfied by any intermediate repayment or satisfaction of all or any of the monies, liabilities and obligations secured by this Agreement and will continue in full force and effect until final repayment in full and total satisfaction of all monies, liabilities and obligations secured by this Agreement; and if upon such final repayment and satisfaction there shall exist any right on the part of the Borrower or any other person to draw funds or otherwise which, if exercised, would or might cause the Borrower to become actually or contingently liable to the Secured Party whether as principal debtor or as surety for another person, then the Secured Party will be entitled to retain this security and all rights, remedies and powers conferred by this Agreement in the Collateral,  for so long as shall or might be necessary to secure the discharge of such actual or contingent liability; and in the event that any demand is made by the Secured Party under this Agreement the said monies will become due and shall be paid and discharged to the Secured Party and all provisions of this Agreement will apply accordingly.


 


(i)            The security constituted by this Agreement will be in addition to and will not operate so as in any way to prejudice or affect any other security which the Secured Party may now or at any time in the future hold for or in respect of all or any part of the monies and liabilities secured by this Agreement, if any, nor will any such other security or any lien to which the Secured Party may be otherwise entitled or the liability of any person not party to this Agreement for all or any part of the monies and liabilities secured by this Agreement be in any way prejudiced or affected by this security.  The Secured Party will have full power at its discretion to give time for payment to or make any other arrangement with any such other person without prejudice to the liability of the Borrower under this Agreement.


 


(j)            If the Obligations covenanted to be paid and discharged in this Agreement have been unconditionally and irrevocably paid and discharged in full the Secured Party shall, as soon as reasonably practicable after such payment and discharge and at the request and cost of the Borrower, execute such documents as may be necessary to release the security created by this Agreement.


 


4.            Events of Default.  The occurrence of any Event of Default under the Secured Agreements, or the breach of any material representation under this Agreement, or the failure to perform any material obligation under Section 3 of this Agreement, shall constitute an “Event of Default” under this Agreement.


 


5.            Remedies on Default.  Upon the occurrence and during the continuance of an Event of Default, Secured Party shall have all rights, privileges, powers and remedies provided by law, including, but not limited to, exercise of any or all of the following remedies.








4








Execution Copy







(a)            Secured Party may declare all amounts outstanding under the Secured Agreements to be immediately due and payable, and thereupon all such amounts shall be and become immediately due and payable to the Secured Party; provided that upon an Event of Default under Section 7.3 of the Loan Agreement, all amounts outstanding shall be immediately due and payable without any action by Secured Party.


 


(b)            Secured Party may dispose of the Collateral in accordance with applicable law.


 


(c)            Secured Party may use, operate, consume and sell the Collateral in its possession as appropriate for the purpose of performing Debtor’s obligations with respect thereto to the extent necessary to satisfy the obligations of Debtor.


 


(d)            All payments received and amounts realized by Secured Party shall be promptly applied and distributed by the Secured Party in the following order of priority:


 


(i)            first, to the payment of all costs and expenses, including reasonable legal expenses and attorneys fees, incurred or made hereunder by Secured Party, including any such costs and expenses of foreclosure or suit, if any, and of any sale or the exercise of any other remedy under this Section 5, and of all taxes, assessments or liens superior to the lien granted under this Agreement; and


 


(ii)          second, to the payment to Secured Party of the amount then owing under the Secured Agreements.


 


6.            Power of Attorney.  Debtor hereby appoints Secured Party, its attorney-in-fact to prepare, sign and file or record, for Debtor in Debtor’s name, any financing statements, applications for registration and like papers and to take any other action deemed by Secured Party necessary or desirable in order to perfect the security interest of the Secured Party hereunder, and, following the occurrence and continuance of an Event of Default, Debtor hereby appoints Secured Party, its attorney-in-fact (i) to dispose of any Collateral, (ii) to perform any obligations of Debtor hereunder, (iii) to commence and prosecute any actions at any court for the purposes of collecting any Collateral and enforcing any other right in respect thereof, (iv) to defend, settle or compromise any action brought and, in connection therewith, give such discharge or release as the Secured Party may deem reasonably appropriate, (v) institute any foreclosure proceedings that the Secured Party may deem appropriate, (vi) to sign and endorse any drafts, assignments, verifications, notices and other documents relating to the Collateral, (vii) to pay or discharge taxes, liens, security interests or other encumbrances levied or placed on or threatened against the Collateral, (viii) to direct any parties liable for any payment in connection with any of the Collateral to make payment of any and all monies due and to become due thereunder directly to the Secured Party or as the Secured Party shall direct, (ix) to receive payment of and receipt for any and all monies, claims, and other amounts due and to become due at any time in respect of or arising out of any Collateral, and (x) do and perform all such other acts and things as the Secured Party may reasonably deem to be necessary, proper or convenient in connection with the Collateral, in each case at Debtor’s expense, but without obligation to do so.








5








Execution Copy







7.            Remedies Cumulative.  Secured Party’s rights and remedies under this Agreement, the Loan Documents, and all other agreements shall be cumulative.  Secured Party shall have all other rights and remedies as provided under the New York Uniform Commercial Code (the “UCC”), by law, or in equity.  No exercise by Secured Party of one right or remedy shall be deemed an election, and no waiver by Secured Party of any Event of Default on Borrower’s or Debtor’s part shall be deemed a continuing waiver.  No delay by Secured Party shall constitute a waiver, election, or acquiescence by it.  No waiver by Secured Party shall be effective unless made in a written document signed on behalf of Secured Party and then shall be effective only in the specific instance and for the specific purpose for which it was given.


 


8.            Notices.  Unless otherwise provided in this Agreement, all notices or demands by any party relating to this Agreement or any other agreement entered into in connection herewith shall be in writing and shall be personally delivered or sent by a recognized overnight delivery service, certified mail, postage prepaid, return receipt requested, or by electronic mail or telefacsimile to Debtor or to Secured Party, as the case may be, at its addresses set forth below:


 


If to Debtor:


 


XOMA (US) LLC


2910 7th Street, No.100


Berkeley, CA 94710


Fax: 510-649-0315


Attn: Chief Financial Officer


Email: kurland@xoma.com







If to Secured Party:


 


Les Laboratoires Servier


50 rue Carnot


92284 Suresnes Cedex, France


Fax: + 33 1 55 72 54 66


Attn: Alliance Manager Business Partenariat Xoma


Email: guillaume.rouland@fr.netgrs.com







The parties hereto may change the address at which they are to receive notices hereunder, by notice in writing in the foregoing manner given to the other.







9.            Dispute Resolution; Choice of Law and Venue.


 



(a)            EACH PARTY HERETO AGREES THAT ANY ACTION, DISPUTE, PROCEEDING, CLAIM OR CONTROVERSY BETWEEN OR AMONG THE PARTIES, OR THEIR SUCCESSORS OR ASSIGNS, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE ARISING IN CONNECTION WITH THIS AGREEMENT, THE LOAN AGREEMENT OR THE XOMA US PROMISSORY NOTE (“DISPUTE” OR “DISPUTES”) SHALL BE FINALLY SETTLED UNDER THE RULES OF ARBITRATION OF THE INTERNATIONAL CHAMBER OF COMMERCE BY ONE OR MORE ARBITRATORS APPOINTED IN ACCORDANCE WITH THE PROVISIONS OF THIS SECTION AND THE SAID RULES.








6








Execution Copy


 




(b)            A SINGLE ARBITRATOR SHALL DECIDE ANY CLAIM OF $100,000 OR LESS. WHERE THE CLAIM OF ANY PARTY IS NOT QUANTIFIED OR EXCEEDS $100,000, THE DISPUTE SHALL BE DECIDED BY A MAJORITY VOTE OF THREE ARBITRATORS.







(c)            THE PLACE OF ARBITRATION SHALL BE IN BRUSSELS, BELGIUM AND THE ARBITRATION SHALL BE HELD IN ENGLISH.







(d)            THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK, NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.


 


(e)            THE ARBITRATOR SHALL NOT HAVE THE POWER OR AUTHORITY TO AWARD PUNITIVE DAMAGES TO ANY PARTY.


 


(f)            THE PARTIES AGREE THAT US PROCEDURAL RULES (INCLUDING DISCOVERY AND CROSS-EXAMINATION) WILL NOT APPLY AND THAT THE ARBITRATORS MAY ORDER DISCLOSURE OF A DOCUMENT ONLY IF AND TO THE EXTENT THAT IT IS HIGHLY RELEVANT TO THE RESOLUTION OF THE DISPUTE; PROVIDED, HOWEVER, THAT ALL PRIVILEGES RESTRICTING DISCLOSURE ESTABLISHED UNDER THE LAWS GOVERNING THIS AGREEMENT SHALL APPLY AND MAY BE INVOKED BY BOTH PARTIES.


 


(g)            JUDGMENT UPON THE AWARD RENDERED MAY BE ENTERED IN ANY COURT HAVING JURISDICTION.


 


No provision of, nor the exercise of any rights under, subsection (a) or subsection (b) above shall limit the right of any party (i) to foreclose against any Collateral, pursuant to applicable provisions of the UCC, or otherwise pursuant to applicable law, (ii) to exercise self help remedies including but not limited to setoff and repossession, or (ii) to request and obtain from a court having jurisdiction before, during or after the pendency of any arbitration provisional or ancillary remedies and relief including but not limited to injunctive or mandatory relief or the appointment of a receiver.  The institution and maintenance of an action or judicial proceeding for, or pursuit of, provisional or ancillary remedies or exercise of self help remedies shall not constitute a waiver of the right of Secured Party, even if Secured Party would otherwise have such right.


 


10.         General Provisions.


 


10.1            Successors and Assigns.  This Agreement shall bind and inure to the benefit of the respective successors and permitted assigns of each of the parties; provided, however, that neither this Agreement nor any rights hereunder may be assigned by Debtor without Secured Party’s prior written consent, which consent may be granted or withheld in Secured Party’s sole discretion.  Secured Party shall have the right without the consent of or notice to Debtor to sell, transfer, negotiate, or grant participation in all or any part of, or any interest in, Secured Party’s obligations, rights and benefits hereunder.


 


10.2            Time of Essence.  Time is of the essence for the performance of all obligations set forth in this Agreement.




 



7







Execution Copy


 


10.3            Severability of Provisions.  Each provision of this Agreement shall be severable from every other provision of this Agreement for the purpose of determining the legal enforceability of any specific provision.


 


10.4            Amendments in Writing, Integration.  This Agreement cannot be amended or terminated orally.  All prior agreements, understandings, representations, warranties, and negotiations between the parties hereto with respect to the subject matter of this Agreement, if any, are merged into this Agreement and the Loan Documents.


 


10.5            Counterparts.  This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Agreement.


 


10.6            Survival.  All covenants, representations and warranties made in this Agreement shall continue in full force and effect so long as any Obligations remain outstanding, any Obligations remain outstanding, or Secured Party has any obligation to make credit extensions to Borrower under the Loan Agreement.  This Agreement shall terminate upon the payment and performance in full of the Obligations.


 


10.7            Terms.  In this Agreement (except where the context otherwise requires):


 


(a)                the singular includes the plural and vice versa and any gender includes the other gender;


 


(b)                words importing persons include natural persons, firms, partnerships, companies, corporations, associations, organisations, governments, states, foundations and trusts (in each case whether or not having a separate legal personality);


 


(c)                any reference to a statute, statutory provision or subordinate legislation (“legislation”) is (unless the contrary is clearly stated) to be construed as a reference to legislation operative in New York and is (except where the context otherwise requires) to be construed as referring to such legislation as amended and in force from time to time and to any legislation which re-enacts or consolidates (with or without modification) any such legislation;


 


(d)                save as otherwise provided in this Agreement, any reference to a section, clause, paragraph, sub-clause, sub-paragraph or schedule is a reference to a section, clause, paragraph, sub-clause, sub-paragraph or schedule (as the case may be) of this Agreement;


 


(e)                the index and headings are inserted for convenience only and are not to affect the construction of this Agreement;


 


(f)                 a reference to any document includes that document as it has or may be amended, varied, assigned, novated, restated or supplemented from time to time;


 


(g)                the Borrower and the Secured Party or any other person shall be construed so as to include its successors in title, permitted assigns and permitted transferees;


 


(h)                any reference to a legal term for any action, remedy, method of judicial proceeding, legal document, legal status, court, official or any legal concept or thing is, in respect of any jurisdiction other than New York, to be deemed to include a reference to what most nearly approximates in that jurisdiction to the legal term under New York law;








8








Execution Copy







(i)                 any phrase introduced by the terms “including”, “include”, “in particular” or any similar expression is to be construed as illustrative and shall not limit the sense of the words preceding those terms.







In Witness Whereof, the parties have executed this Agreement on the date set forth above.


 


	
Debtor:

	 	
Secured Party:


	
XOMA (US) LLC

	 	
LES LABORATOIRES SERVIER


	 		 		 
	
By:

	     	 	
By:

	     
	
Name:

	 	 	
Name:

	 
	
Title:

	 	 	
Title:

	 









9








EXHIBIT 10.74







Execution Copy


 





	DEBTOR:	XOMA (US) LLC






	SECURED PARTY:	LES LABORATOIRES SERVIER










EXHIBIT A







COLLATERAL DESCRIPTION ATTACHMENT


TO SECURITY AGREEMENT







The following personal property of Debtor:







1. All of Debtor’s right, title and interest in that certain Transfer Agreement relating to the Intellectual Property Rights (as defined below), effective as of December 30, 2010, by and between XOMA Technology Ltd. and XOMA Ireland Limited, which rights of XOMA Ireland Limited have been assigned to and assumed by Debtor pursuant to that certain Asset Transfer Agreement, dated as of August     , 2013;







2. All of Debtor’s right, title and interest in the patents and patent applications in the Licensed Territory listed in Schedule A hereto (including any rights transferred under the above mentioned December 30, 2010 Transfer Agreement), including any and all related continuations, continuations in-part, divisions, extensions, reissues, re-examinations, renewals or substitutions, any and all other proprietary rights related to the foregoing (including, without limitation, remedies against infringements thereof and rights of protection of and interest therein under the laws of all jurisdictions) in the Licensed Territory (as defined below).







“Licensed Territory” means all countries of the world other than (a) the United States of America, and (b) Japan, including their respective territories and possessions.













SCHEDULE A







FAMILY 1



	Title:	IL1-Beta binding antibodies and fragments thereof






	Inventors:	Linda Masat; Mary Haak-Frendscho; Gang Chen; Arnold Horwitz; Marina Roell










	
COUNTRY

	
APPLICATION NO.

	
FILE DATE

	
PATENT/PUBLICATION


	
US Provisional

	
61/692,830

	
06/21/05

	 
	
PCT

	
PCT/US06/024261

	
06/21/06

	
WO2007/002261


	
Australia

	
2006 262179

	
06/21/06

	
2006262179 B2


	
Brazil

	
PI0612273-6

	
06/21/06

	
BRPI0612273 A2


	
Canada

	
2,612,760

	
06/21/06

	
CA2612760 A1


	
China

	
2006 80026551.9

	
06/21/06

	
CN101228188 A


	
China

	
201210157441.3

	
05/18/12

	
CN102775493A


	
EP (all countries):

	
06773749.4

	
06/21/06

	
1899378


	
Austria

	
06773749.4

	
06/21/06

	
1899378


	
Belgium

	
06773749.4

	
06/21/06

	
1899378


	
Bulgaria

	
06773749.4

	
06/21/06

	
1899378


	
Cyprus

	
06773749.4

	
06/21/06

	
1899378


	
Czech Republic

	
06773749.4

	
06/21/06

	
1899378


	
Denmark

	
06773749.4

	
06/21/06

	
1899378


	
Estonia

	
06773749.4

	
06/21/06

	
E004059


	
Finland

	
06773749.4

	
06/21/06

	
1899378


	
France

	
06773749.4

	
06/21/06

	
1899378


	
Germany

	
06773749.4

	
06/21/06

	
60 2006 010 072.8-08


	
Greece

	
06773749.4

	
06/21/06

	
3070850


	
Hungary

	
06773749.4

	
06/21/06

	
E 007716


	
Iceland

	
06773749.4

	
06/21/06

	
1899378


	
Ireland

	
06773749.4

	
06/21/06

	
1899378


	
Italy

	
06773749.4

	
06/21/06

	
73749BE/2009


	
Latvia

	
06773749.4

	
06/21/06

	
1899378


	
Lithuania

	
06773749.4

	
06/21/06

	
1899378


	
Luxembourg

	
06773749.4

	
06/21/06

	
1899378


	
Monaco

	
06773749.4

	
06/21/06

	
1899378


	
Netherlands

	
06773749.4

	
06/21/06

	
1899378


	
Poland

	
06773749.4

	
06/21/06

	
1899378


	
Portugal

	
06773749.4

	
06/21/06

	
1899378


	
Romania

	
06773749.4

	
06/21/06

	
RO/EP 1 899 378


	
Slovak Republic

	
06773749.4

	
06/21/06

	
1899378


	
Slovenia

	
06773749.4

	
06/21/06

	
1899378


	
Spain

	
06773749.4

	
06/21/06

	
1899378


	
Sweden

	
06773749.4

	
06/21/06

	
1899378


	
Switzerland

	
06773749.4

	
06/21/06

	
1899378


	
Turkey

	
06773749.4

	
06/21/06

	
TR 2009 09878 T4


	
United Kingdom

	
06773749.4

	
06/21/06

	
1899378


	
EP

	
09 174 190.0

	
10/27/09

	
2 163 562 A2


	
EP

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Austria

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Belgium

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Bulgaria

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Cyprus

	
10 179 088.9

	
09/23/10

	
2314623 B1





 









Execution Copy


 




	
Czech Republic

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Denmark

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Estonia

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Finland

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
France

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Germany

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Greece

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Hungry

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Iceland

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Ireland

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Italy

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Latvia

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Lithuania

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Liechtenstein

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Luxembourg

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Monaco

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Netherlands

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Poland

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Portugal

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Romania

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Spain

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Sweden

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Slovenia

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Slovak Republic

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Switzerland

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
Turkey

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
United Kingdom

	
10 179 088.9

	
09/23/10

	
2314623 B1


	
EP

	
10 179 089.7

	
09/23/10

	
2 322 552 A2


	
Hong Kong

	
09100795.8

	
06/21/06

	
1123560


	
Hong Kong

	
10107181.2

	
07/27/10

	
1140781A


	
Hong Kong

	
11111525.8

	
10/26/11

	
1157351 B


	
Hong Kong

	
11112428.4

	
11/17/11

	
1158218A


	
Israel

	
188094

	
06/21/06

	
188094


	
Israel

	
202630

	
12/09/09

	
202630


	
India

	
320/CHENP/2008

	
06/21/06

	 
	
Korea

	
10-2008-7001520

	
06/21/06

	
KR 20080039875 A


	
Mexico

	
MX/a/2007/016032

	
06/21/06

	
282003


	
Mexico

	
MX/a/2010/002638

	
03/08/10

	 
	
New Zealand

	
565138

	
06/21/06

	
565138


	
Philippines

	
1-2007-502895

	
06/21/06

	
1-2007-502895


	
Russian Federation

	
2008102135

	
06/21/06

	
RU 2008102135 A


	
Singapore

	
200718904-6

	
06/21/06

	
140638


	
South Africa

	
2008/00555

	
06/21/06

	
2008/00555





 


FAMILY 2



	Title:	Methods for Treatment of IL-1Beta Related Diseases






	Inventors:	Alan M. Solinger; Patrick J. Scannon; Robert J. Bauer; David Alleva










	
COUNTRY

	
APPLICATION NO.

	
FILE DATE

	
PATENT/PUBLICATION


	
US Provisional

	
60/871,046

	
12/20/06

	 
	
US Provisional

	
60/908,389

	
03/27/07

	 
	
US Provisional

	
60/911,033

	
04/10/07

	 
	
PCT

	
PCT/US2007/088411

	
12/20/07

	
WO 2008/077145


	
Europe

	
07869675.4

	
12/20/07

	
EP2094306 A2


	
Australia

	
2007333635

	
12/20/07

	
AU2007333635 A1





 



3







Execution Copy


 


	
Brazil

	
PI 0720928-2

	
12/20/07

	 
	
Canada

	
2,673,592

	
12/20/07

	 
	
China

	
200780051536.4

	
12/20/07

	
CN 101616690A


	
Hong Kong

	
10102012.8

	
02/25/10

	
1135323A


	
India

	
4626/DELNP/2009

	
12/20/07

	 
	
Indonesia

	
W00 2009 01721

	
12/20/07

	
050.2064A


	
Mexico

	
MX/a/2009/006709

	
12/20/07

	
299543


	
Russia

	
2009127066

	
12/20/07

	 
	
South Africa

	
2009/04660

	
12/20/07

	
2009/04660










FAMILY 3



	Title:	Methods for Treatment of Gout






	Inventors:	Alan M. Solinger










	
COUNTRY

	
APPLICATION NO.

	
FILE DATE

	
PATENT/PUBLICATION


	
US Provisional

	
61/015,633

	
12/20/07

	 
	
US Provisional

	
61/059,378

	
06/06/08

	 
	
US Provisional

	
61/095,191

	
09/08/08

	 
	
PCT

	
PCT/US08/087519

	
12/18/08

	
WO 2009/086003


	
Australia

	
2008343085

	
07/12/10

	 
	
Canada

	
2,710,252

	
12/18/08

	 
	
China

	
200880126879.7

	
12/18/08

	 
	
EP

	
08866346.3

	
07/19/10

	
2 391 650 A1


	
Mexico

	
MX/a/2010/006823

	
06/18/10

	
293693


	
Russia

	
2010129783

	
07/20/10

	 









4







FAMILY 4



	Title:	Methods for the Treatment of Rheumatoid Arthritis






	Inventors:	Alan M. Solinger, Alexander Owyang










	
COUNTRY

	
APPLICATION NO.

	
FILE DATE

	
PATENT/PUBLICATION


	
US Provisional

	
61/059,711

	
06/06/08

	 
	
US Provisional

	
61/095,232

	
09/08/08

	 
	
PCT

	
PCT/US09/46441

	
06/05/09

	
WO 2009/149370


	
Canada

	
2,727,171

	
12/06/10

	 
	
Australia

	
2009256072

	
12/14/10

	 
	
Europe:

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Austria

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Belgium

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Bulgaria

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Croatia

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Cyprus

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Czech Repub

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Denmark

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Estonia

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Finland

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
France

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Germany

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Greece

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Hungary

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Iceland

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Ireland

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Italy

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Latvia

	
09 759 528.4

	
12/22/10

	
2293816 B1





 



5








Execution Copy


 




	
Lithuania

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Luxembourg

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Macedonia

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Malta

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Monaco

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Netherlands

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Norway

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Poland

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Portugal

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Romania

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Slovak Repub

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Slovenia

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Spain

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Sweden

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Switzerland/


 Liechtenstein

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
Turkey

	
09 759 528.4

	
12/22/10

	
2293816 B1


	
UK

	
09 759 528.4

	
12/22/10

	
2293816 B1





 


FAMILY 5



	Title:	Methods for Treating or Preventing IL-1Beta Related Diseases






	Inventors:	Patrick J. Scannon, Alan M. Solinger, Robert J. Bauer





	
COUNTRY

	
APPLICATION NO.

	
FILE DATE

	
PATENT/PUBLICATION


	
US Provisional

	
61/094,842

	
09/05/08

	 
	
US Provisional

	
61/121,451

	
12/10/08

	 
	
PCT

	
PCT/US09/56086

	
09/04/09

	
WO 2010/028275


	
Australia

	
2009289547

	
03/03/11

	 
	
Canada

	
2,735,940

	
03/02/11

	 
	
Europe

	
09 812 306.0

	
04/04/11

	
2 341 936 A1





 


FAMILY 6



	Title:	METHODS FOR IMPROVEMENT OF BETA CELL FUNCTION






	Inventors:	Patrick J. Scannon, Alan M. Solinger, Robert J. Bauer










	
COUNTRY

	
APPLICATION NO.

	
FILE DATE

	
PATENT/PUBLICATION


	
US Provisional

	
61/094,857

	
09/05/08

	 
	
US Provisional

	
61/121,486

	
12/10/08

	 
	
PCT

	
PCT/US09/56084

	
09/04/09

	
WO 2010/028273


	
Australia

	
2009289545

	
03/03/11

	 
	
Canada

	
2,735,939

	
03/02/11

	 
	
Europe

	
09 812 304.5

	
04/04/11

	
2 341 935 A1










FAMILY 7



	Title:	CARDIOVASCULAR RELATED USES OF IL-1β ANTIBODIES AND BINDING FRAGMENTS THEREOF






	Inventors:	Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein





 


	
COUNTRY

	
APPLICATION NO.

	
FILE DATE

	
PATENT/PUBLICATION


	
US Provisional

	
61/182,679

	
05/29/09

	 
	
US Provisional

	
61/252,571

	
10/16/09

	 
	
US Provisional

	
61/313,001

	
03/11/10

	 
	
PCT

	
PCT/US10/36761

	
05/28/10

	
WO 2010/138939





 



6








Execution Copy


 




	
Australia

	
2010253924

	
05/28/10

	 
	
Australia

	
2013203560

	
04/10/13

	 
	
Brazil

	
PI1011228-6

	
11/29/11

	 
	
Canada

	
2,763,161

	
05/28/10

	 
	
China

	
201080033031.7

	
05/28/10

	
 CN 102573893A


	
EPO

	
10 781 360.2

	
12/20/11

	
 EP 2 435 073 A1


	
Eurasia

	
201101643

	
12/15/11

	 
	
Hong Kong

	
12108509.3

	
08/XX/12

	
 1167814A


	
India

	
9944/DELNP/2011

	
12/16/11

	 
	
Indonesia

	
W00 2011 04690

	
12/21/11

	
 2012/01714 A


	
Israel

	
216660

	
11/28/11

	 
	
Korea

	
10-2011-7031198

	
12/27/11

	
 10-2012-006104


	
Mexico

	
MX/a/2011/012666

	
11/28/11

	 
	
New Zealand

	
597024

	
11/12/11

	 
	
Philippines

	
1-2011-502479

	
11/28/11

	 
	
Singapore

	
201108772-3

	
11/28/11

	 
	
South Africa

	
2011/09050

	
12/08/11

	 








FAMILY 8



	Title:	Methods for the treatment of IL-1Beta related conditions






	Inventors:	Alan M. Solinger, Ahmet Gül





	
COUNTRY

	
APPLICATION NO.

	
FILE DATE

	
PATENT/PUBLICATION


	
US Provisional

	
61/332,658

	
05/07/10

	 
	
US Provisional

	
61/334,125

	
05/12/10

	 
	
US Provisional

	
61/444,638

	
02/18/11

	 
	
PCT

	
PCT/US11/35646

	
05/06/11

	
 WO 2011/140522


	
Australia

	
2011249854

	
05/06/11

	 
	
Australia

	
2013203214

	
04/09/13

	 
	
Brazil

	
BR 11 2012 028557 2

	
05/06/11

	 
	
Canada

	
2,797,846

	
05/06/11

	 
	
China

	
201180022684.X

	
05/06/11

	
 2013-509314


	
Europe

	
11778465.2

	
05/06/11

	
 2 566 520 A


	
Eurasia

	
201201526

	
05/06/11

	 
	
India

	
9496/DELNP/2012

	
05/06/11

	 
	
Indonesia

	
W00201204922

	
05/06/11

	 
	
Israel

	
222890

	
05/06/11

	 
	
Korea

	
10-2012-7031454

	
05/06/11

	 
	
Mexico

	
MX/a/2012/012901

	
05/06/11

	 
	
New Zealand

	
603191

	
05/06/11

	 
	
Philippines

	
1-2012-502143

	
05/06/11

	 
	
Singapore

	
201208230-1

	
05/06/11

	 
	
South Africa

	
2012/08172

	
05/06/11

	 








FAMILY 9*



	Title:	METHODS FOR TREATING ACNE






	Inventors:	Paul Rubin










	
COUNTRY

	
APP. NO.

	
FILE DATE

	
PATENT/PUBLICATION


	
US Provisional

	
61/577,450

	
12/19/11

	 
	
PCT

	
PCT/US12/70734

	
12/19/12

	 








*Future ROW (non-US, non-Japan) rights








7







Execution Copy


EXHIBIT 2







PROMISSORY NOTE


 


€15,000,000


August __, 2013


Berkeley, California


 


For Value Received, XOMA (US) LLC, a Delaware limited liability company (“Borrower”), hereby promises to pay to the order of LES LABORATOIRES SERVIER, a corporation organized under the laws of France (“Lender”), the principal sum of Fifteen Million Euros (€15,000,000) (the “Loan”) together with accrued and unpaid interest thereon, each due and payable on the dates and in the manner set forth below.







This Promissory Note is the Note referred to in and is executed and delivered in connection with that certain Security Agreement, dated as of even date herewith, executed by Borrower in favor of Lender (as the same may from time to time be amended, modified or supplemented or restated, the “Security Agreement”), and that certain Loan Agreement, dated as of December 30, 2010, as amended, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented or restated, the “Loan Agreement”), among other agreements.  Additional rights and obligations of Lender are set forth in the Security Agreement and the Loan Agreement.  All capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Loan Agreement and the Security Agreement.


 


1.            Original Note; Loan Agreement.  This Promissory Note replaces the Promissory Note, dated as of January 13, 2011, issued by Xoma Ireland Limited to Lender (the “Original Note”).  Lender shall deliver the cancelled Original Note to Xoma Ireland Limited upon its receipt of this Promissory Note, executed by the Borrower.  This Promissory Note shall be the Note referred to in the Loan Agreement and is entitled to the benefits of all provisions of the Loan Agreement.  All references in the Loan Agreement to the “Note” shall be deemed to refer to this Promissory Note.


 


2.            Principal Repayment.  The total outstanding principal amount of the indebtedness evidenced by this Promissory Note shall be due and payable in accordance with the terms of the Loan Agreement.  Demand, diligence, presentment, protest and notice of non-payment and protest are hereby waived by the Borrower.


 


3.            Interest Rate.  Borrower further promises to pay interest on the outstanding principal amount hereof at the rate or rates per annum and in the manner set forth in the Loan Agreement, or the maximum rate permissible by law, whichever is less.


 


4.            Payment on Non-Business Day.  In the event that any payment of any principal, interest, fees or other amounts payable by Borrower under or pursuant to the Loan Agreement, or under any other Loan Document shall become due on any day which is not a Business Day, such due date shall be extended to the next succeeding Business Day, further provided that no interest shall accrue from and during any such extension.


 


5.            Default.   Upon the occurrence and during the continuance of an Event of Default under the Loan Agreement or any of the other Loan Documents, all unpaid principal, accrued interest and other amounts owing hereunder shall become due and payable as provided in the Loan Agreement and the Lender shall have all rights and remedies against the Borrower as provided in the Loan Agreement, the Security Agreement and under applicable law.








8








Execution Copy







6.            Secured Note.  The full amount of this Note is secured by the Collateral identified and described as security therefore in the Security Agreement executed by and delivered by Borrower to Lender.  Borrower shall not, directly or indirectly, create, permit or suffer to exist, and shall defend the Collateral against and take such other action as is necessary to remove, any Lien on or in the Collateral, or in any portion thereof.


 


7.            Representations and Warranties.  By its execution hereof, Borrower hereby represents and warrants that each of the representations and warranties contained in the Loan Agreement and the other Loan Documents shall be true and correct as of the date hereof, provided that each reference in such provisions to XOMA Ireland shall be deemed to refer to the Borrower.


 


8.            Governing Law.  This Note shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.  The provisions of Section 9 of the Security Agreement are hereby incorporated by reference (including with respect to arbitration) and this Promissory Note and the parties hereto shall otherwise be subject to all of the terms and conditions of Section 9 of the Security Agreement, mutatis mutandis.


 


9.            Successors and Assigns.  The provisions of this Note shall inure to the benefit of and be binding on any successor to Borrower and shall extend to any holder hereof.







	
Borrower

	
XOMA (US) LLC


 


	 	
By:            

	     
	 	
 


Printed Name:

	     
	 	
 


Title:            

	      









9









Execution Copy


 




EXHIBIT 3







Dated                     2013







XOMA IRELAND LIMITED







as Chargor


 


LES LABORATOIRES SERVIER







as Chargee







and







DEED OF RELEASE







Re: Fixed Equitable Charge dated 13 January 2011







A & L GOODBODY








10







Execution Copy




THIS DEED OF RELEASE is dated                    2013 and made between:







(1)                XOMA IRELAND LIMITED, a company incorporated in Ireland with registration number 307875 and having its registered office at 26 Pembroke Street Upper, Dublin 2, Ireland (the Chargor); and







(2)                LES LABORATOIRES SERVIER, a company organised and existing under the laws of France having its principal place of business at 50 rue Carnot, 92284 Suresnes, France (the Chargee).







WHEREAS:







A.                By a fixed charge dated 13 January 2011 between the Chargor and Chargee in respect of the Loan Agreement, the Chargor has granted security to the Chargee for the payment and discharge of the Obligations (the Fixed Charge).







B.                 Pursuant to a consent, transfer and assumption agreement dated the date hereof between the Chargor, the Chargee and XOMA (US) LLC (the Consent, Transfer, Assumption and Amendment Agreement) the Chargee has agreed to release the Chargor in full from its obligations under the Fixed Charge and has agreed to do so on and subject to the terms of this Deed.







WITNESSES as follows:








	1.	DEFINITIONS AND INTERPRETATION










Unless the context otherwise requires, terms used and not defined shall have the same meaning given to them in the Fixed Charge.







Indebtedness has the same meaning as in the Loan Agreement;







Intellectual Property Rights has the same meaning as in the Loan Agreement;







Loan Agreement means the loan agreement dated 30 December, 2010 between the Chargor and the Chargee pursuant to which the Chargee made a loan available to the Chargor, as amended from time to time;







Loan Documents has the same meaning as in the Loan Agreement;







Obligations has the same meaning as in the Loan Agreement;







Transfer Agreement means the transfer agreement between Xoma Technology Ltd. and the Chargor dated 30 December 2010 relating to the Intellectual Property Rights;








	2.	DISCHARGE AND RELEASE










2.1.            In accordance with the terms of the Fixed Charge, the Chargee hereby irrevocably and unconditionally








11








Execution Copy










		2.1.1.	RELEASES and DISCHARGES unto the Chargor, to the extent charged by way of security in favour of the Chargee pursuant to the Fixed Charge, all rights, interests and titles in and to the Transfer Agreement present or future;











		2.1.2.	RELEASES and DISCHARGES unto the Chargor, to the extent charged by way of security in favour of the Chargee pursuant to the Fixed Charge, all rights, interests and titles in and to the Intellectual Property Rights, including without limitation, all Intellectual Property Rights specified in the schedule attached to the Fixed Charge; and











		2.1.3.	RELEASES and DISCHARGES the Chargor from all obligations, absolute and contingent, pursuant to the Fixed Charge and all claims and demands thereunder, so that such obligations, claims and demands are, with effect from the execution and delivery of this Deed, discharged and of no further effect.










2.2.            The Chargor and the Chargee hereby agree that the Fixed Charge be and is hereby terminated.








	3.	INVALIDITY










3.1.            If a provision of this Deed is or becomes illegal, invalid or unenforceable in any jurisdiction, that will not affect:








		3.1.1.	the legality, validity or enforceability in that jurisdiction of any other provision of this Deed; or











		3.1.2.	the legality, validity or enforceability in any other jurisdiction of that or any other provision of this Deed.










The illegal, invalid or unenforceable provision shall be substituted by a valid provision which accomplishes as far as legally possible the economic purposes of the void or unenforceable provision.








	4.	REPRESENTATIONS AND WARRANTIES










4.1.            Each of the parties hereto hereby represents and warrants that:








		4.1.1.	it has full power and authority to execute, deliver and perform its obligations under this Deed; and











		4.1.2.	this Deed constitutes its legal, valid and binding obligations enforceable against it in accordance with its terms.











	5.	FURTHER ASSURANCES










The Chargee shall, at the cost and expense of the Chargor, from time to time sign, seal, execute, acknowledge, deliver, file and register, all such further and additional documents, instruments, agreements, certificates, consents and assurances and do all such other acts and things as may be reasonably required by the Chargor for the purpose of more effectively carrying out the intent and purpose of this Deed.








12








Execution Copy










	6.	COUNTERPARTS










This Deed may be executed in any number of counterparts and by the different parties to this Deed on different counterparts each of which, when executed and delivered, shall constitute an original, but all the counterparts shall together constitute but one and the same instrument.








	7.	GOVERNING LAW










This Deed shall be governed by and construed in accordance with the laws of Ireland.







IN WITNESS whereof the parties have executed and delivered this Deed on the date at the beginning of this Deed.







GIVEN UNDER THE COMMON SEAL OF


XOMA IRELAND LIMITED







LES LABORATORIES SERVIER







	
By:

	      	 
	
Name:

	     	 
	
Title:

	     	 









13







Execution Copy





EXHIBIT 4


 




CONFIRMATION OF SATISFACTION







Pursuant to Section 3.1 of that certain Consent, Transfer, Assumption and Amendment Agreement dated August ___, 2013 (the “Loan Transfer Consent”), by and among XOMA Ireland, XOMA US and Servier, the undersigned as [INSERT TITLE] of Servier hereby confirms and declares that it has received from XOMA US (i) confirmation of the completion of the GEVO Asset Transfer, (ii) the signed XOMA US Note and (iii) the fully signed Security Agreement; and that the Conditions have thus been satisfied as of the Transfer Completion Date (all capitalized terms shall have the meanings assigned thereto in the Loan Transfer Consent).







	 	
For and on behalf of LES LABORATOIRES SERVIER

	
	 	 		
	 	
By:

	      	
	 	
Name:

	      	
	 	
Title:

	     	
	 	
Date:

	     	





 


 








14